-- Zip（ASX：ZIP）周四向澳大利亚证券交易所提交的文件显示，4月份集团整体增长势头持续强劲，美国业务总交易额（TTV）同比增长超过40%（以美元计）。 该公司表示，美国信贷业绩符合预期，有望在第四财季将信贷支出控制在TTV的1.75%以下。 Zip重申了2026财年的业绩指引，包括集团税前折旧摊销前现金收益（EBTDA）超过2.6亿澳元，美国业务TTV同比增长超过40%（以美元计），以及集团营业利润率超过18%。 该公司补充道，其他业绩指引指标包括集团营收利润率约为8%，集团现金EBTDA占TTV的比例超过1.4%，以及集团现金净交易利润率在3.8%至4.2%之间。
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661